Lazabemide
Source: Wikipedia, the free encyclopedia.
Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C8H10ClN3O |
| Molar mass | 199.64 g·mol−1 |
Lazabemide (proposed trade names Pakio, Tempium) is a
reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1]
References
| Dopaminergics |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anticholinergics | |||||||||||
| Others | |||||||||||
| |||||||||||